T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines

Steven M. Horwitz; Stephen Ansell; Weiyun Z. Ai; Jeffrey Barnes; Stefan K. Barta; Mark W. Clemens; Ahmet Dogan; Aaron M. Goodman; Gaurav Goyal; Joan Guitart; Ahmad Halwani; Bradley M. Haverkos; Richard T. Hoppe; Eric Jacobsen; Deepa Jagadeesh; Allison Jones; Youn H. Kim; Neha Mehta-Shah; Elise A. Olsen; Barbara Pro; Saurabh A. Rajguru; Sima Rozati; Jonathan Said; Aaron Shaver; Andrei Shustov; Lubomir Sokol; Pallawi Torka; Carlos Torres-Cabala; Ryan Wilcox; Basem M. William; Jasmine Zain; Mary A. Dwyer; Hema Sundar

doi:10.6004/JNCCN.2020.0053

T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines

Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara ProSaurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Original language	English (US)
Pages (from-to)	1460-1467
Number of pages	8
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	11
DOIs	https://doi.org/10.6004/JNCCN.2020.0053
State	Published - Nov 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/JNCCN.2020.0053

Cite this

Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., Dogan, A., Goodman, A. M., Goyal, G., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Jones, A., Kim, Y. H., Mehta-Shah, N., Olsen, E. A., ... Sundar, H. (2020). T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 18(11), 1460-1467. https://doi.org/10.6004/JNCCN.2020.0053

Horwitz, SM, Ansell, S, Ai, WZ, Barnes, J, Barta, SK, Clemens, MW, Dogan, A, Goodman, AM, Goyal, G, Guitart, J, Halwani, A, Haverkos, BM, Hoppe, RT, Jacobsen, E, Jagadeesh, D, Jones, A, Kim, YH, Mehta-Shah, N, Olsen, EA, Pro, B, Rajguru, SA, Rozati, S, Said, J, Shaver, A, Shustov, A, Sokol, L, Torka, P, Torres-Cabala, C, Wilcox, R, William, BM, Zain, J, Dwyer, MA & Sundar, H 2020, 'T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 11, pp. 1460-1467. https://doi.org/10.6004/JNCCN.2020.0053

@article{01a7b73a1b174900b990c90bb528b21f,

title = "T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines",

abstract = "Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.",

author = "Horwitz, {Steven M.} and Stephen Ansell and Ai, {Weiyun Z.} and Jeffrey Barnes and Barta, {Stefan K.} and Clemens, {Mark W.} and Ahmet Dogan and Goodman, {Aaron M.} and Gaurav Goyal and Joan Guitart and Ahmad Halwani and Haverkos, {Bradley M.} and Hoppe, {Richard T.} and Eric Jacobsen and Deepa Jagadeesh and Allison Jones and Kim, {Youn H.} and Neha Mehta-Shah and Olsen, {Elise A.} and Barbara Pro and Rajguru, {Saurabh A.} and Sima Rozati and Jonathan Said and Aaron Shaver and Andrei Shustov and Lubomir Sokol and Pallawi Torka and Carlos Torres-Cabala and Ryan Wilcox and William, {Basem M.} and Jasmine Zain and Dwyer, {Mary A.} and Hema Sundar",

year = "2020",

month = nov,

doi = "10.6004/JNCCN.2020.0053",

language = "English (US)",

volume = "18",

pages = "1460--1467",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines

AU - Horwitz, Steven M.

AU - Ansell, Stephen

AU - Ai, Weiyun Z.

AU - Barnes, Jeffrey

AU - Barta, Stefan K.

AU - Clemens, Mark W.

AU - Dogan, Ahmet

AU - Goodman, Aaron M.

AU - Goyal, Gaurav

AU - Guitart, Joan

AU - Halwani, Ahmad

AU - Haverkos, Bradley M.

AU - Hoppe, Richard T.

AU - Jacobsen, Eric

AU - Jagadeesh, Deepa

AU - Jones, Allison

AU - Kim, Youn H.

AU - Mehta-Shah, Neha

AU - Olsen, Elise A.

AU - Pro, Barbara

AU - Rajguru, Saurabh A.

AU - Rozati, Sima

AU - Said, Jonathan

AU - Shaver, Aaron

AU - Shustov, Andrei

AU - Sokol, Lubomir

AU - Torka, Pallawi

AU - Torres-Cabala, Carlos

AU - Wilcox, Ryan

AU - William, Basem M.

AU - Zain, Jasmine

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2020/11

Y1 - 2020/11

N2 - Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

AB - Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=85095784379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095784379&partnerID=8YFLogxK

U2 - 10.6004/JNCCN.2020.0053

DO - 10.6004/JNCCN.2020.0053

M3 - Review article

C2 - 33152703

AN - SCOPUS:85095784379

SN - 1540-1405

VL - 18

SP - 1460

EP - 1467

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this